Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925337 | 0.86 | KMT2A (0.45) | ALDH1A1KMT2AMEN1MAPTPKM | |
| SCHEMBL2917089 | 0.85 | RAB9A (0.46) | KMT2AMAPTRECQLLMNA | |
| SCHEMBL2915231 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1MAPTCLK4 | |
| SCHEMBL2923776 | 0.83 | KMT2A (0.47) | ALDH1A1KMT2AMEN1MAPTPKM | |
| SCHEMBL2924634 | 0.83 | IDH1 (0.42) | ALDH1A1KMT2AMEN1MAPTPKM | |
| SCHEMBL2922347 | 0.82 | METAP2 (0.43) | ALDH1A1KMT2AMEN1MAPTPKM | |
| SCHEMBL2920855 | 0.81 | KMT2A (0.48) | ALDH1A1KMT2AMAPTPKMLMNA | |
| SCHEMBL2923604 | 0.80 | FAAH (0.49) | KMT2AMEN1POLBKDRFLT3 | |
| SCHEMBL2914047 | 0.80 | CCNA2 (0.44) | ALDH1A1KMT2AMEN1MAPTPKM | |
| SCHEMBL2914214 | 0.80 | NTRK1 (0.42) | ALDH1A1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| US-8273765-B2 | Bicyclo-pyrazoles and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-09-25 | — | — | US | disclosed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
| EP-1320531-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 4090/4885KMT2A 2789/4885MEN1 3952/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | ALDH1A1 3455/4885KMT2A 3607/4885MEN1 4143/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 4090/4885KMT2A 2789/4885MEN1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.